Oncopeptides is a privately held clinical stage pharmaceutical company developing oncology therapies centered on peptidase targeting. Melflufen, Oncopeptides lead drug compound, is a peptidase potentiated therapy in clinical development. Melflufen is a very potent anti-angiogenic compound that triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.
Orphan Drug Designation for melflufen in the Treatment of Multiple Myeloma has been granted by EMA and FDA. Melflufen is currently undergoing Phase II efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The study is being carried out across six centers; in Sweden, Italy, the Netherlands, Denmark and the US (two sites) – with Dana Faber Cancer Institute, Boston, MA being the lead investigator site.